Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-group, Phase 2, Randomized, Double-blind, Placebo-controlled, 4-arm, 12-week Trial to Investigate the Efficacy, Safety, and Tolerability of COL-5671-PRO Oral Capsules in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT07914231 is registered in ClinicalTrials.gov with Coultreon Biopharma as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07914231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-group, Phase 2, Randomized, Double-blind, Placebo-controlled, 4-arm, 12-week Trial to Investigate the Efficacy, Safety, and Tolerability of COL-5671-PRO Oral Capsules in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Coultreon Biopharma
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2027
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis

Arms

As registered; 4 arms.

  • COL-5671-PRO Treatment A ExperimentalCOL-5671-PRO

    Participant will receive dose A of COL-5671-PRO capsules orally once daily (QD) for 12 weeks.

  • COL-5671-PRO Treatment B ExperimentalCOL-5671-PRO

    Participant will receive dose B of COL-5671-PRO capsules orally once daily (QD) for 12 weeks.

  • COL-5671-PRO Treatment C ExperimentalCOL-5671-PRO

    Participant will receive dose C of COL-5671-PRO capsules orally once daily (QD) for 12 weeks.

  • Placebo Placebo comparatorPlacebo

    Participant will receive placebo to match COL-5671-PRO capsules orally once daily (QD) for 12 weeks.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Reduction of 75% in PASI score relative to baseline (PASI75) at Week 12 From enrollment to the end of treatment at 12 weeks

    The Psoriasis Area and Severity Index (PASI) combines assessments of the extent of body-surface involvement in 4 anatomical regions (head and neck, upper limbs, trunk, lower limbs) and the severity of erythema, induration, and desquamation in each region, yielding an overall score of 0 to 72. A frequency table of participants with a reduction of 75% in PASI score relative to baseline (PASI75) at Week 12 per intervention arm.

Similar trials

Same condition (Psoriasis) and phase, most recent start first.